Lisata Therapeutics, Inc. (LSTA)

NASDAQ: LSTA · IEX Real-Time Price · USD

2.780

-0.090 (-3.14%)

At close: Apr 17, 2024, 3:55 PM

2.740

-0.040 (-1.44%)

After-hours: Apr 17, 2024, 4:00 PM EDT

Lisata Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1995
Net Income	-20.84	-54.23	-27.47	-8.15	-19.36	-16.17	22.98	-32.66	-80.89	-54.87	Upgrade
Depreciation & Amortization	0.19	0.07	0.06	0.06	0.07	0.23	0.37	0.45	2.69	2.19	Upgrade
Share-Based Compensation	2.04	2.64	2.01	1.27	1.3	2.45	1.96	1.77	9.75	11.21	Upgrade
Other Operating Activities	-1.42	30.35	3.16	-2	-0.88	-6.5	-46.19	6.76	29.19	-5.42	Upgrade
Operating Cash Flow	-20.03	-21.17	-22.25	-8.82	-18.88	-19.99	-20.88	-23.67	-39.26	-46.9	Upgrade
Capital Expenditures	0	-0.29	-0.06	-0.02	0	-0.13	-0.14	-1.1	-3.19	-3.66	Upgrade
Acquisitions	0	-3.32	0	0	0	2.55	67.88	0	0	0.05	Upgrade
Change in Investments	10.1	32.52	-54.84	-7.26	21.43	-7.12	-26.29	0	6.98	-7.13	Upgrade
Other Investing Activities	-	-	-	-	-	-	-0.19	-1.75	-	-	Upgrade
Investing Cash Flow	10.1	28.91	-54.9	-7.28	21.43	-4.71	41.27	-2.85	3.8	-10.74	Upgrade
Share Issuance / Repurchase	0.48	0.04	85.52	18.73	1.31	1.39	5.72	11.56	36.47	18.7	Upgrade
Debt Issued / Paid	0	0	0	0	0	-0.16	-6.22	-9.58	0.13	11.97	Upgrade
Other Financing Activities	-0.09	-0.27	-0.25	-0.15	-0.13	-0.4	-0.43	18.92	-	-	Upgrade
Financing Cash Flow	0.39	-0.22	85.28	18.58	1.18	0.82	-0.93	20.9	36.6	30.67	Upgrade
Exchange Rate Effect	-0.02	-0.01	0	0	0	0	0	0	0	0	Upgrade
Net Cash Flow	-9.56	7.51	8.14	2.48	3.73	-23.87	19.46	-5.61	1.14	-26.96	Upgrade
Free Cash Flow	-20.03	-21.46	-22.31	-8.84	-18.88	-20.12	-21.01	-24.77	-42.44	-50.55	Upgrade
Free Cash Flow Margin	-	-	-	-	-	-	-	-	-188.74%	-281.81%	Upgrade
Free Cash Flow Per Share	-2.48	-4.14	-6.05	-8.59	-27.43	-31.15	-35.14	-56.73	-131.24	-231.48	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).